Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Jens Plaschke - , Department of Surgical Research (Author)
  • Stefan Krüger - , Department of Surgical Research (Author)
  • Wolfgang Dietmaier - , University of Regensburg (Author)
  • Johannes Gebert - , University of Regensburg (Author)
  • Christian Sutter - , University of Regensburg (Author)
  • Elisabeth Mangold - , University of Bonn Medical Center (Author)
  • Constanze Pagenstecher - , University of Bonn Medical Center (Author)
  • Elke Holinski-Feder - , Ludwig Maximilian University of Munich (Author)
  • Karsten Schulmann - , University Hospital Knappschaftskrankenhaus Bochum GmbH (Author)
  • Gabriela Möslein - , Heinrich Heine University Düsseldorf (Author)
  • Josef Rüschoff - , Klinikum Kassel GmbH (Author)
  • Christoph Engel - , Leipzig University (Author)
  • Gareth Evans - , Manchester University NHS Foundation Trust (Author)
  • Hans K. Schackert - , Department of Surgical Research (Author)

Abstract

Germline mutations in mismatch repair (MMR) genes, predominantly in MLH1 and MSH2, are responsible for hereditary nonpolyposis colorectal cancer (HNPCC), a cancer-susceptibility syndrome with high penetrance. In addition, MSH6 mutations have been reported to account for about 10% of all germline mismatch repair (MMR) gene mutations in HNPCC patients, and have been associated with a later age of onset of the disease compared to MLH1 and MSH2 mutations. Here, we report eight novel germline mutations in MSH6. The patients were selected by having developed tumors with loss of MSH6 protein expression. All tumors showed high-level microsatellite instability (MSI-H). Seven mutations resulted in premature stop codons, comprised of two nonsense mutations (c.426G>A [p.W142X], c.2105C>A [p.S702X]), two insertions (c.2611_2614dupATTA [p.I872fsX10], c.3324dupT [p.I1109fsX3]) and three deletions (c.1190_1191delAT [p.Y397fsX3], c.1632_1635delAAAA [p.E544fsX26], c.3513_3514delTA [p.1171fsX5]). In addition, an amino acid substitution of an arginine residue (c.2314C>T [p.R772W]) conserved throughout a wide variety of mutS homologs has been found in a patient not fulfilling the Bethesda criteria for HNPCC. Our results emphasize the suitability of IHC as a pre-selection tool for MSH6 mutation analysis and the high frequency of germline mutation detection in patients with MSH6-deficient tumors. In addition, our findings point towards a broad variability regarding penetrance associated with MSH6 germline mutations.

Details

Original languageEnglish
Pages (from-to)285
Number of pages1
JournalHuman mutation
Volume23
Issue number3
Publication statusPublished - Mar 2004
Peer-reviewedYes

External IDs

PubMed 14974087

Keywords

Sustainable Development Goals

ASJC Scopus subject areas